Physician profile
Mary D Blades
NPI 1306842042
$732.53
in general payments reported to CMS, 2019-2025
17 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $14.23 · 2022: $79.31 · 2023: $171 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $113.07 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $98.59 | 2019-2023 | |
| Atricure, INC. | $90.02 | 2023 | |
| Lilly USA, LLC | $81.87 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $54.99 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $50.48 | 2019-2023 | Xarelto |
| Abbvie INC. | $49.42 | 2019-2025 | Vraylar |
| Amgen INC. | $46.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.83 | 2019 | |
| Antares Pharma, INC. | $17.00 | 2019 | |
| Astellas Pharma US INC | $16.00 | 2023 | Myrbetriq |
| Allergan, INC. | $15.93 | 2019 | |
| Pulmonx Corporation | $14.93 | 2022 | |
| Horizon Therapeutics Plc | $13.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.20 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.50 | 2019 | |
| Hikma Pharmaceuticals USA | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Blades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.